medigraphic.com
Órgano Oficial del Instituto Nacional de Pediatría

2008, Number 1

<< Back Next >>

Acta Pediatr Mex 2008; 29 (1)

Frequency of drug consumption and lack of pediatric formulations

Flores-Pérez C, Flores-Pérez J, Juárez-Olguín H, Barranco-Garduño LM

Language: English
References: 24
Page: 1-5
PDF size: 116.23 Kb.


ABSTRACT

Background: The lack of pediatric drug formulations is a problem that has limited the prescription in that population in the long term, resulting errors in drug administration by patients. Objetive: To determine the frequency of drug consumption at a National Pediatrics Institute in a six year-period, and identify those medications for which there is no available pediatric formulation. Methods: The frequency of consumption of medications was investigated, using the data base at the Pharmacy of the National Pediatrics Institute during the period from January 2001 to June 2006. Drugs were grouped according to their frequency, identifying those not available for pediatric use which are nevertheless prescribed. Results:. About 85 different drugs were used to attend hospital demands, which were prescribed on 7514 occasions within the period of study. The most frequently used drugs were: ranitidine (4.7 %), paracetamol (3.8 %) and midazolam (3.7 %). Our results showed that midazolam, furosemide, phenobarbital, omeprazole, prednisone and captopril were the most prescribed drugs for which there are no pediatric formulations commercially available. Conclusion: This article reports the frequency of drug consumption at a pediatric hospital and discusses it in view of the lack of adequate formulations for pediatric patients in our country.


REFERENCES

  1. Antonakis N, Xylouri I, Alexandrakis M, Cavoura C, Lionis C.Seeking prescribing patterns in rural Crete: a pharmacoepidemiological study from a primary care area. Rural Remote Health 2006; 6(1): 488.

  2. Jackevicious CA, Tu K, Filate WA, Brien SE, Tu JV. Trends in cardiovascular drug utilization and drug expenditures, in Canada between 1996-2001. Can. J. Cardiol. 2003; 19(12):1359-66.

  3. Dineshkumar B, Raghuram TC, Radhaiah G, Krishnaswamy K. Profile of drug use in urban and rural India. Pharmacoeconomics 1995; 7(4):332-46.

  4. Copeland C. Consumption drugs: issues of cost, coverage and quality. EBRI Issue Brief 1999; 208: 1-21.

  5. Chico AP, Hidalgo FJ, Pérez GG, Camacho VA, Guillé PA, De la Roca J, Lares AI,. Juárez OH,. Prescribing patterns and consumption of medication in a rural community in Mexico. Journal of Pharmacy Practice and Research 2003; 33(4): 330.

  6. Juárez OH, Flores PJ, Lares AI, Montes OI. Perfil de consumo de antibióticos en un hospital pediátrico de la ciudad de México. Perinatol. Reprod. Hum. 1998; 12: 157-62.

  7. Juárez OH, Camacho VA, Guillé PA, Hernández AG, Pérez GG,Saltigeral SP. Uso de antibióticos en las enfermedades infecciosas de recién nacidos. Acta Pediatr. Mex. 2004; 25(3): 175-9.

  8. Ramírez MJ, Garrido GL, Villalobos CC y cols. Ranitidina y alteraciones electrocardiograficas en niños. Alerg. Asma Inmunol. Pediatr. 2001; 10(2): 40-2.

  9. Ramírez MJ, Cervantes BR, Mata RN y cols. Determinación de pH intraesofágico por 24 horas en niños con reflujo gastroesofágico y asma de reciente diagnóstico tratados con ranitidina. Rev. Alerg. Asma Inmunol. Pediatr. 2000; 9(6): 188-90.

  10. Flores PC, Juárez OH, Flores PJ, Ramírez MB, Bobadilla CJ. A simple method to measure plasma levels of propafenone with fluorescence detection. Chromatographia 2005; 62: 373-7.

  11. Juárez OH, Flores PC, Flores PJ, Ramírez MB, Carrasco PM,Bobadilla CJ. Bioavailability of an extemporaneous suspension of propafenone made from tablets. Biopharm. Drug Dispos. 2006; 27: 241-5.

  12. Norma Oficial Mexicana NOM-073-SSA1-1993.Estabilidad de medicamentos. In: Diario Oficial de la Federación, México.

  13. Farmacopea de los Estados Unidos Mexicanos FEUM, vol. I and II, 8th edn. México, 2004; 39, 1351-61.

  14. Alfonso RG. Remington. Farmacia, 19th edn. Medica Panamericana:Buenos Aires, Argentina, 1998; 1735-1748, 2291- 2308.

  15. Johnson CE, Streetman DD. Stability of oral suspensions of ursodiol made from tablets. Am. J. Health Syst. Pharm. 2002; 59: 361-3.

  16. Vandenbussche HL, Johnson CE, Fontana EM, Meram JM.Stability of levofloxacin in an extemporaneously compounded oral liquid. Am. J. Health Syst. Pharm. 1999; 56: 2316-8.

  17. Real Decreto Español 175/2001. Normas de correcta elaboración y control de calidad de formulas magistrales y preparados oficinales.

  18. Normas de recomendación, Argentina, 2002. Buenas practicas de elaboración profesional de medicamentos magistrales y preparados oficinales.

  19. Mishra LD, Sinha GK, Bhaskar Rao P, Sharma V, Satga K,Gairola R. Injectable midazolam as oral premedicant in pediatric neurosurgery. J. Neurosurg. Anesthesiol. 2005; 17(4):193-8.

  20. Burnett JE and Balkin ER. Stability and viscosity of a flavored omeprazole oral suspension for pediatric use. Am. J. Health Syst. Pharm. 2006; 63: 2240-7.

  21. Glass BD, Haywood A. Stability considerations in liquid dosage form extemporaneously prepared from commercially available products. J. Phar. Pharm. Sci. 2006; 9(3): 398-426.

  22. Brion F, Nunn AJ, Rieutord A. Extemporaneous (magistral) preparation of oral medicines for children in European hospitals. Acta Paediatr. 2003; 92(4): 408-10.

  23. Ghulam A, Keen K, Tuleu C, Wrong IC, Long PF. Poor preservation efficacy versus quality and safety of pediatric extemporaneous liquids. Ann. Pharmacother. 2007; 41(5): 857-60.

  24. Nahata MC, Morosco RS, Brady MT. Extemporaneous sildenafil citrate oral suspensions for the treatment of pulmonary hypertension in children. Am. J. Health Syst. Pharm. 2006; 63:254-7.




2020     |     www.medigraphic.com